Cigna director granted 782 CI shares

MAZZARELLA KATHLEEN M reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

MAZZARELLA KATHLEEN M reported acquisition or exercise transactions in this Form 4 filing.

Cigna Group director Kathleen M. Mazzarella received an equity grant of 782 shares of Cigna common stock. The award was recorded at a price of $0.00 per share, indicating it was a compensation-related grant rather than a market purchase. After this grant, she directly holds 6,891 Cigna shares.

Insider Trade Summary

Grant/Award: 782 shares

Grant/Award 1 txn

Insider MAZZARELLA KATHLEEN M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $.01 Par Value	782	$0.00	$0.00

Holdings After Transaction: Common Stock, $.01 Par Value — 6,891 shares (Direct)

Key Figures

Shares granted: 782 shares Grant price: $0.00 per share Shares held after grant: 6,891 shares

3 metrics

Shares granted 782 shares Equity award to director on 2026-04-22

Grant price $0.00 per share Compensation-related stock grant

Shares held after grant 6,891 shares Director’s direct holdings post-transaction

Key Terms

Common Stock, $.01 Par Value, Grant, award, or other acquisition, Form 4

3 terms

Common Stock, $.01 Par Value financial

"security_title: Common Stock, $.01 Par Value"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 regulatory

"INSIDER FILING DATA (Form 4): {"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cigna Group (CI) report for Kathleen M. Mazzarella?

Cigna reported that director Kathleen M. Mazzarella received a grant of 782 shares of common stock. The shares were awarded at $0.00 per share as part of compensation, increasing her direct holdings to 6,891 shares after the transaction.

Was the Cigna (CI) insider transaction a market purchase or a grant?

The transaction was a grant or award of 782 Cigna common shares, not a market purchase. It carried a price of $0.00 per share, indicating compensation-related equity rather than an open-market buy. This is a routine form of director compensation.

How many Cigna (CI) shares does Kathleen M. Mazzarella hold after this Form 4 filing?

After receiving the 782-share grant, Kathleen M. Mazzarella directly holds 6,891 Cigna common shares. This post-transaction balance reflects her updated ownership position as reported in the Form 4 insider filing for this award.

What does transaction code A mean in the Cigna (CI) Form 4 filing?

Transaction code A in this Cigna Form 4 indicates a grant, award, or other acquisition of shares. Here, it reflects a 782-share equity award to director Kathleen M. Mazzarella as compensation, rather than a purchase or sale in the open market.

Is the Cigna (CI) insider transaction by Kathleen M. Mazzarella a buy or a sale?

The Form 4 shows an acquisition through a grant, not a buy or sale. Mazzarella received 782 Cigna shares as a compensation-related award at $0.00 per share, raising her direct holdings to 6,891 shares after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 04:53 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAZZARELLA KATHLEEN M

(Last) (First) (Middle)

900 COTTAGE GROVE ROAD

(Street)

BLOOMFIELD CONNECTICUT 06002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.01 Par Value	04/22/2026		A		782	A	$0	6,891	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	Tyler Gratton, attorney-in-fact	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)